(AOF) – Implanet, a medical technology company specializing in spinal implants, announces the signing of an agreement with SMTP Technology Co (a high-tech medical company specializing in the manufacture and sale of ultrasound surgical equipment) for the distribution exclusive in France of its latest generation ultrasonic surgical scalpel. This scalpel is able to support both open surgery, minimally invasive surgery and endoscopic intervertebral spine surgery.
This product, which has obtained marketing authorizations for China, the European Union and the United States, stands out for its innovative mode of operation guaranteeing better safety for patients and practitioners during surgery.
The agreement concluded today between Implanet and SMTP Technology Co. follows the signature of the distribution contract and the technological partnership signed with Sanyou Medical, of which SMTP Technology Co. is one of the subsidiaries. This new agreement includes the exclusive distribution of the scalpel by Implanet on the French market.
AOF – LEARN MORE
An inevitable race for new blockbusters
The patent for Merck’s star product, the cancer drug Keytruda, which accounts for more than 35% of its sales, expires in 2028. Despite the loss, since 2019, of the patents for its three star products (Avastin, Herceptine, Rituxan) Roche was able to renew its portfolio by bringing new molecules to market. However, the discovery and launch of new drugs are increasingly expensive. AstraZeneca spends about $6 billion a year on R&D in a pharmaceutical industry where the life of a patent only lasts ten to fifteen years. This leads laboratories to withdraw from certain activities. Thus J&J, Pfizer, GSK and, no doubt, Novartis soon prefer to refocus on specialty drugs and abandon any ancillary activity.